In humans, a crossover study from agonist (leuprolide) to antagonist (degarelix) demonstrated better prostate cancer control with the latter, with a significant decrease in serum prostate-specific antigen (PSA) concentration (9), which was ascribed to the concomitant FSH suppression. This evidence concerns the gene BRD2 and prostate carcinoma.